{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:26Z","timestamp":1761506066854,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.cllc.2021.01.011","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T12:06:14Z","timestamp":1611749174000},"page":"e708-e711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4012-3251","authenticated-orcid":false,"given":"Guilherme","family":"Harada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-3375","authenticated-orcid":false,"given":"Mariane Tami","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda Frozoni","family":"Antonacio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Henkin","family":"Behar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Henrique Xavier","family":"Nabuco-de-Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0956-2790","authenticated-orcid":false,"given":"Carlos Alberto","family":"Buchpiguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilberto de Castro","family":"Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2018","series-title":"SEER Cancer Statistics Review, 1975-2015","author":"Noone AM","key":"10.1016\/j.cllc.2021.01.011_bib0001"},{"key":"10.1016\/j.cllc.2021.01.011_bib0002","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.01.011_bib0003","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.01.011_bib0004","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40425-016-0153-x","article-title":"PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?","volume":"4","author":"Grigg","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cllc.2021.01.011_bib0005","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/onc.2009.4","article-title":"The SWI\/SNF complex and cancer","volume":"28","author":"Reisman","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.cllc.2021.01.011_bib0006","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1158\/0008-5472.CAN-05-1225","article-title":"The p270 (ARID1A\/SMARCF1) subunit of mammalian SWI\/SNF-related complexes is essential for normal cell cycle arrest","volume":"65","author":"Nagl","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2021.01.011_bib0007","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1007\/s13277-014-1755-x","article-title":"ARID1A is downregulated in non-small cell lung cancer and regulates cell proliferation and apoptosis","volume":"35","author":"Zhang","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cllc.2021.01.011_bib0008","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/humu.21633","article-title":"Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types","volume":"33","author":"Jones","year":"2012","journal-title":"Hum Mutation"},{"key":"10.1016\/j.cllc.2021.01.011_bib0009","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.canlet.2020.01.001","article-title":"ARID1A deficiency and immune checkpoint blockade therapy: from mechanisms to clinical application","volume":"473","author":"Hu","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cllc.2021.01.011_bib0010","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2021.01.011_bib0011","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2021.01.011_bib0012","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2021.01.011_bib0013","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2021.01.011_bib0014","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/PPO.0000000000000301","article-title":"PD-L1 and emerging biomarkers in immune checkpoint blockade therapy","volume":"24","author":"Cottrell","year":"2018","journal-title":"Cancer J"},{"key":"10.1016\/j.cllc.2021.01.011_bib0015","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jtho.2020.04.026","article-title":"Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC","volume":"15","author":"Hong","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2021.01.011_bib0016","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cllc.2021.01.011_bib0017","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"New Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.cllc.2021.01.011_bib0018","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1200\/JCO.2020.38.15_suppl.9530","article-title":"Impact of SWI\/SNF complex mutations in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors: immuno-oncology biomarker study in LC-SCRUM-Japan (LC-SCRUM-IBIS)","volume":"38","author":"Yoh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.cllc.2021.01.011_bib0019","doi-asserted-by":"crossref","first-page":"9523","DOI":"10.1200\/JCO.2020.38.15_suppl.9523","article-title":"Prevalence and association of ARID1A with driver alterations and immune checkpoint inhibitor (ICPi) biomarkers in cell-free circulating tumor DNA (ctDNA) from 27,000 non-small cell lung cancer (NSCLC) patients","volume":"38","author":"Gandara","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.01.011_bib0020","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med"},{"issue":"15_suppl","key":"10.1016\/j.cllc.2021.01.011_bib0021","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1200\/JCO.2020.38.15_suppl.3540","article-title":"A pan-cancer analysis of ARID1A as a potential biomarker for immune checkpoint therapy","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.01.011_bib0022","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/PAI.0000000000000575","article-title":"Microsatellite instability: a predictive biomarker for cancer immunotherapy","volume":"26","author":"Chang","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.cllc.2021.01.011_bib0023","doi-asserted-by":"crossref","first-page":"e000438","DOI":"10.1136\/jitc-2019-000438","article-title":"ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1\/PD-L1 immunotherapy","volume":"8","author":"Okamura","year":"2020","journal-title":"J Immuno Ther Cancer"},{"key":"10.1016\/j.cllc.2021.01.011_bib0024","article-title":"ARID1A mutation may define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer","volume":"7","author":"Mehrvarz Sarshekeh","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.cllc.2021.01.011_bib0025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the mystic phase 3 randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2021.01.011_bib0026","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/j.jtho.2019.08.428","article-title":"OA04.07 mutations associated with sensitivity or resistance to immunotherapy in mNSCLC: analysis from the MYSTIC trial","volume":"14","author":"Rizvi","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2021.01.011_bib0027","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s10020-020-00208-9","article-title":"Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer","volume":"26","author":"Sun","year":"2020","journal-title":"Mol Med (Cambridge, Mass)"},{"issue":"15_suppl","key":"10.1016\/j.cllc.2021.01.011_bib0028","doi-asserted-by":"crossref","first-page":"9549","DOI":"10.1200\/JCO.2020.38.15_suppl.9549","article-title":"Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC)","volume":"38","author":"Luo","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730421000140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730421000140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:11:36Z","timestamp":1761505896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730421000140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1525730421000140"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2021.01.011","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2021.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}